Home  >  News
Research + Font Resize -

ReMYND, Novo Nordisk enter license pact to develop ReS39 therapeutic programme of diabetes

Leuven Belgium
Friday, December 15, 2017, 18:00 Hrs  [IST]

reMYND, a spin-off from the University of Leuven, and Novo Nordisk, a global healthcare company,  have entered into a license agreement to further develop reMYND’s ReS39 therapeutic programme of diabetes. This programme holds also promise for NASH and the metabolic syndrome.

reMYND’s lead diabetes programme ReS39 sustains and increases the endogenous insulin production capacity of the pancreas by restoring beta-cell function and insulin signalling in type 1 and type 2 diabetes animal models.

Koen De Witte, managing director of reMYND commented “Even though symptomatic treatments work well, diabetes patients would greatly benefit from restoring durably their endogenous insulin production and/or increasing insulin sensitivity. Novo Nordisk’s agility to step-in once they observed the effects of our ReS39 treatment in their own hands makes the road ahead all the more exciting.”

Under the agreement, reMYND could receive up to 350 million Euros in research and milestone payments, plus royalties on resulting net sales.

With the support of Vlaams Agentschap Innoveren en Ondernemen (VLAIO) and Participatie Maatschappij Vlaanderen (PMV), reMYND has discovered and developed its lead diabetes programme ReS39. These compounds sustain and increase the endogenous insulin production capacity and insulin signalling in diabetes animal models, providing fast symptomatic relief combined with durability. In addition, ReS39 reduces liver weight and its triglyceride content, making it potentially also relevant for NASH and the metabolic syndrome.

The programme has previously shown a similar protective effect on dopamine producing neurons in Parkinson’s mice, the most common motor disorder.

Currently the preclinical candidate is being profiled to take into pre-clinical toxicology studies.

reMYND NV, founded in 2002 as a spin-off from the University of Leuven, drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, diabetes, and other orphan protein misfolding disorders.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |